A growing number of long-term series document highly favorable outcomes after brachytherapy
or prostatectomy for low-risk prostate cancer (
1
,
2
,
3
). And unlike the case for external beam radiation, the effectiveness of prostate brachytherapy
can be measured by post-treatment prostate-specific antigens that match those of prostatectomy
(
[4]
). Studies documenting long-term cancer control in younger patients specifically are
more limited, but available evidence is that the prognosis for younger patients with
either surgery or brachytherapy is similar to that for older patients (
1
,
2
). Quality-of-life outcomes also seem similar between modalities overall, regardless
of age (
5
,
6
). Although excellent outcomes can be achieved with surgery or brachytherapy in younger
prostate cancer patients, it has become clear that achieving those outcomes with either
modality is quality dependent.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Brachytherapy in men aged ≤54 years with clinically localized prostate cancer.BJU Int. 2006; 98: 324-328
- Outcomes for men younger than 50 years undergoing radical prostatectomy.Urology. 2005; 66: 141-146
- Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy.Urology. 2006; 67: 769-773
- Comparison of biochemical failure definitions for permanent prostate brachytherapy.Int J Radiat Oncol Biol Phys. 2006; 65: 1487-1493
- Quality of life and satisfaction with outcomes among prostate-cancer survivors.N Eng J Med. 2008; 358: 1250-1261
- Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer.Urology. 2005; 65: 1157-1162
- The surgical learning curve for prostate cancer control after radical prostatectomy.J Natl Cancer Inst. 2007; 99: 1171-1177
- Laparoscopic radical prostatectomy: Six months of fellowship training doesn't prevent the learning curve when incorporating into a lower volume practice.Urol Oncol. 2009; 27: 144-148
- A dose-response study for I-125 prostate implants.Int J Radiat Oncol Biol Phys. 1998; 41: 101-108
- There is a wide range of predictive dosimetric factors for I-125 and Pd-103 prostate brachytherapy.Am J Clin Oncol. 2007; 31: 6-10
- A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.Am J Clin Oncol. 2007; 30: 199-204
- Defining the risk of developing grade 2 proctitis following 125-I prostate brachytherapy using a rectal dose-volume histogram analysis.Int J Radiat Oncol Biol Phys. 2001; 50: 335-341
- Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy.Int J Radiat Oncol Biol Phys. 1995; 32: 465-471
- Long-term prostate cancer control using Palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.Urology. 2007; 69: 334-337
- Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.Int J Radiat Oncol Biol Phys. 2007; 68: 34-40
- Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.Int J Radiat Oncol Biol Phys. 2006; 66: 389-394
- Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason score of 8 to 10.Cancer. 2006; 107: 1265-1272
- Impact of prostate-specific antigen on the clinical and pathologic outcomes after radical prostatectomy for Gleason 8-10 cancers.BJU Int. 2007; 101: 299-304
- Interstitial brachytherapy should be standard of care for treatment of high risk prostate cancer.Oncology (Williston Park). 2008; 22 (discussion 1006, 1011–1017. Review): 995-1004
- Extracapsular dose distribution following permanent prostate brachytherapy.Am J Clin Oncol. 2003; 26: 178-189
- The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy.Cancer. 1999; 85: 2630-2637
Article Info
Publication History
Published online: July 01, 2010
Identification
Copyright
© 2010 Published by Elsevier Inc.
